Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands:a nation-wide retrospective cohort study
OBJECTIVES: The recent accelerated FDA approval of sotorasib, a highly selective KRAS G12C inhibitor, offers new opportunities for the treatment of KRAS p.(G12C)-mutated non-squamous non-small cell lung cancer (NSCLC). The objective of the current study was to the determine the prevalence of KRAS mutations in stage IV non-squamous NSCLC in The Netherlands to reveal the potential impact of upcoming KRAS targeted therapy. MATERIALS AND METHODS: All patients diagnosed with stage IV non-squamous NSCLC in 2013, 2015 and 2017 in the Netherlands were selected by linking the nation-wide Netherlands Ca... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2022 |
| Reihe/Periodikum: | Garcia , B N C , van Kempen , L C , Kuijpers , C C H J , Schuuring , E , Willems , S M & van der Wekken , A J 2022 , ' Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands : a nation-wide retrospective cohort study ' , Lung Cancer , vol. 167 , pp. 1-7 . https://doi.org/10.1016/j.lungcan.2022.03.015 |
| Schlagwörter: | Non-Small Cell Lung Cancer / KRAS / KRAS p / (G12C) / Predictive biomarkers / Molecular diagnostics / Sotorasib / CELL LUNG-CANCER / K-RAS / MUTATIONS / EGFR / ADENOCARCINOMA / INHIBITORS / FREQUENCY / ONCOGENE / MEDICINE / SURVIVAL |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-29190957 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://hdl.handle.net/11370/5136f528-534d-4b2c-8e1d-a2c6390a0d60 |
